NFKB1 and neoplasm: These results are in accordance with other studies which indicate BET inhibitors can modulate the transcription of NF-κB target genes in macrophages [23], renal tubular epithelial cells [40], tumour cells [41, 42] and rheumatoid fibroblast‐like synoviocytes [43].